News Release
RCMG Inc. is pleased to announce that the first clinical study paper for HBsAgGi ELISA, entitled “Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy” has been published in BMC Gastroenterology (https://pubmed.ncbi.nlm.nih.gov/35641912/).
The new study aimed to evaluate serum HBsAgGi levels in 47 patients with chronic hepatitis B (CHB) treated with nucleos(t)ide analogs (NAs).
Comparison of HBsAgGi levels with other markers (HBV-DNA, HBsAg, and HBcrAg) at the baseline and after 48 weeks of NA therapy demonstrated that the HBsAgGi levels significantly correlated with HBV-DNA. Both HBV-DNA and HBsAgGi levels were decreased after 48 weeks of NA therapy, indicating HBsAgGi as a novel potential biomarker to monitor infectious HBV particles in patients receiving NA therapy. Immunoprecipitation assays demonstrated that the HBsAgGi antibody can enrich HBV particles containing HBV-RNA as well as HBV-DNA. Thus, the paper indicates the usefulness of the HBsAgGi in clinical study of HBV.
*Our research team previously found that the HBsAgGi (HB surface antigen glycan isomer) antibody is a monoclonal antibody specific to O-glycosylated PreS2 on M-HBs, which is predominantly expressed by HBV-DNA-containing viral particles.
“O-glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection”
Angata et al. (2021) Biochim Biophys Acta Gen Subj. 1866:130020
https://pubmed.ncbi.nlm.nih.gov/34582939/
HBsAgGi antibody and HBsAgGi ELISA kit, which can measure infectious HBV particles described above are now available for research use only and can be purchased from RCMG Inc. and our distributor, FUJIFILM Wako Pure Chemical Corporation.
More detail information is available at our Projects and Research Products page.
